TP53 and neoplasm: This idea gained support in a study where Rb1/Tp53-mutant genetically engineered mouse models (GEMMs) with the homozygous or heterozygous deletion of Rbl2 showed significantly higher tumor incidence and shorter tumor latency compared to those with wild-type Rbl2 [13].